PF-04457845

Generic Name
PF-04457845
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C23H20F3N5O2
CAS Number
1020315-31-4
Unique Ingredient Identifier
H4C81M8YYW
Background

PF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.

Associated Conditions
-
Associated Therapies
-

A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2014-08-13
Last Posted Date
2016-06-29
Lead Sponsor
Pfizer
Target Recruit Count
14
Registration Number
NCT02216097
Locations
๐Ÿ‡บ๐Ÿ‡ธ

NYU CTSI Research Pharmacy (Drug Shipment Address), New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Clinical and Translational Science Institute (CTSI), New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

NYU School of Medicine, New York, New York, United States

FAAH Inhibitor Trial for Adults With Tourette Syndrome

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2014-05-08
Last Posted Date
2018-10-29
Lead Sponsor
Yale University
Target Recruit Count
5
Registration Number
NCT02134080
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Connecticut Mental Health Center, New Haven, Connecticut, United States

Cannabinoid Augmentation of Fear Response in Humans

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-08-15
Last Posted Date
2022-03-11
Lead Sponsor
Yale University
Target Recruit Count
31
Registration Number
NCT01665573
Locations
๐Ÿ‡บ๐Ÿ‡ธ

VA Connecticut Healthcare System, West Haven, Connecticut, United States

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-06-13
Last Posted Date
2023-02-23
Lead Sponsor
Yale University
Target Recruit Count
70
Registration Number
NCT01618656
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Yale University School of Medicine, New Haven, Connecticut, United States

A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-09-22
Last Posted Date
2017-09-19
Lead Sponsor
Pfizer
Target Recruit Count
76
Registration Number
NCT00981357
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Arthritis & Rheumatic Care Center, Miami, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

CEDRA Clinical Research, LLC, San Antonio, Texas, United States

๐Ÿ‡ธ๐Ÿ‡ช

Centrum for klinisk provning, Goteborg, Sweden

and more 3 locations

Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-06-11
Last Posted Date
2009-07-10
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT00918164
Locations
๐Ÿ‡ธ๐Ÿ‡ฌ

Pfizer Investigational Site, Singapore, Singapore

ยฉ Copyright 2024. All Rights Reserved by MedPath